TrxR1 Cancer Research Results

TrxR1, thioredoxin reductase 1: Click to Expand ⟱
Source:
Type:
TrxR1 or TXNRD1 (Thioredoxin Reductase 1)
Redox Control, Stress Tolerance, and Therapy Resistance
• Many studies have found that an elevated expression of TrxR1 in breast tumors, NSCLC, HCC correlates with increased tumor aggressiveness and a poorer prognosis.
-TrxR1 expression was elevated by >50 fold in FaDu and HeLa cells, and by >20 fold in SCC-1 compared to either MSK-Leuk1 or keratinocytes.

High TXNRD1 expression often associates with:
-Advanced stage
-Therapy resistance
-Reduced survival

TrxR1 Inhibition
-Collapses redox control
-Causes rapid ROS accumulation
-Triggers apoptosis, especially in high-stress tumors


GC, Gastric Adenocarcinoma: Click to Expand ⟱
Stomach/Gastric Cancer
Scientific Papers found: Click to Expand⟱
7159- CHA,    ROS-mediated inactivation of the PI3K/AKT pathway is involved in the antigastric cancer effects of thioredoxin reductase-1 inhibitor chaetocin
- vitro+vivo, GC, HGC27 - in-vitro, GC, AGS - in-vitro, GC, BGC-823 - in-vitro, GC, SGC-7901 - in-vitro, Nor, HEK293
TumCP↓, TumCCA↑, Casp↑, Apoptosis↑, TrxR1↓, ROS↑, eff↓, eff↑, PI3K↓, Akt↓, TumCG↓, cl‑PARP↑, cl‑Casp3↑, cl‑Casp9↑, cl‑Casp8↑, Bcl-2↓, Bcl-xL↓, Mcl-1↓, XIAP↓, survivin↓, TumVol↓, TumW↓, Weight∅, toxicity↓, Ki-67↓, other↝,
1947- PL,    Piperlongumine as a direct TrxR1 inhibitor with suppressive activity against gastric cancer
- in-vitro, GC, SGC-7901 - in-vitro, GC, NA
TrxR1↓, ROS↑, ER Stress↑, mtDam↑, selectivity↑, NO↑, TumCCA↑, mt-ROS↑, Casp9↑, Bcl-2↓, Bcl-xL↓, cl‑PARP↑, eff↓, lipid-P↑,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

lipid-P↑, 1,   ROS↑, 2,   mt-ROS↑, 1,   TrxR1↓, 2,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

mtDam↑, 1,   XIAP↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 1,   Apoptosis↑, 1,   Bcl-2↓, 2,   Bcl-xL↓, 2,   Casp↑, 1,   cl‑Casp3↑, 1,   cl‑Casp8↑, 1,   Casp9↑, 1,   cl‑Casp9↑, 1,   Mcl-1↓, 1,   survivin↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↝, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

ER Stress↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

cl‑PARP↑, 2,  

Cell Cycle & Senescence(tgid=11) ⓘ

TumCCA↑, 2,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

PI3K↓, 1,   TumCG↓, 1,  

Migration(tgid=13) ⓘ

Ki-67↓, 1,   TumCP↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

NO↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

eff↓, 2,   eff↑, 1,   selectivity↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

Ki-67↓, 1,  

Functional Outcomes(tgid=23) ⓘ

toxicity↓, 1,   TumVol↓, 1,   TumW↓, 1,   Weight∅, 1,  
Total Targets: 34

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: TrxR1, thioredoxin reductase 1
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:28  Cells:%  prod#:%  Target#:1207  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page